Search
forResearch 10 of 1000+
- Alopecia in patients treated with molecularly targeted anticancer therapies
- Molecular targeted therapies for cancer: Sorafenib mono�therapy and its combination with other therapies (Review)
- Skin toxicity of anti‐cancer therapy
- 329 Mechanisms of Cutaneous Adverse Events during Targeted Cancer Therapy
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects
- Recent Insights into the Potential and Challenges of Sericin as a Drug Delivery Platform for Multiple Biomedical Applications
- Understanding, recognizing, and managing toxicities of targeted anticancer therapies
- Toll-like receptor-targeted anti-tumor therapies: Advances and challenges
- Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: A pooled analysis
Learn
— no results
Try a deeper search in learn →Community
— no results
Try a deeper search in community →